Does IMATINIB Cause Second primary malignancy? 763 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 763 reports of Second primary malignancy have been filed in association with IMATINIB (Imatinib). This represents 1.8% of all adverse event reports for IMATINIB.
763
Reports of Second primary malignancy with IMATINIB
1.8%
of all IMATINIB reports
171
Deaths
132
Hospitalizations
How Dangerous Is Second primary malignancy From IMATINIB?
Of the 763 reports, 171 (22.4%) resulted in death, 132 (17.3%) required hospitalization, and 16 (2.1%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for IMATINIB. However, 763 reports have been filed with the FAERS database.
What Other Side Effects Does IMATINIB Cause?
Death (9,708)
Drug ineffective (2,628)
Nausea (2,379)
Diarrhoea (2,203)
Fatigue (1,810)
Malignant neoplasm progression (1,716)
Vomiting (1,599)
Malaise (1,361)
Drug intolerance (1,354)
Drug resistance (1,293)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
METHOTREXATE (414)
Which IMATINIB Alternatives Have Lower Second primary malignancy Risk?
IMATINIB vs IMBRUVICA
IMATINIB vs IMDEVIMAB
IMATINIB vs IMEGLIMIN
IMATINIB vs IMETELSTAT
IMATINIB vs IMIDAPRIL